Currency In USD
| Previous Close | 79.54 |
| Open | 79 |
| Day High | 80.82 |
| Day Low | 78.13 |
| 52-Week High | 93.42 |
| 52-Week Low | 62.5 |
| Volume | 1.4M |
| Average Volume | 2.71M |
| Market Cap | 15.24B |
| PE | -25.73 |
| EPS | -3.04 |
| Moving Average 50 Days | 69.89 |
| Moving Average 200 Days | 72.69 |
| Change | -1.31 |
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
GlobeNewswire Inc.
Mar 11, 2026 6:00 PM GMT
- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified subgroups - Early separation from placebo observed
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
GlobeNewswire Inc.
Mar 04, 2026 12:30 PM GMT
PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data fro
BridgeBio to Participate in March Investor Conferences
GlobeNewswire Inc.
Feb 23, 2026 12:30 PM GMT
PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its manag